Table 1. Base case probabilities and sources.

Probabilities (per month)			Base Case Value	Duration	Range Tested in Sensitivity Analyses	Distribution used in PSA±	Source
Cetuximab-related adverse events:
Mild events including infusion-related allergies and skin reactions (grade 1 or 2)			29.2%	First month on cetuximab	25 % – 32.9 %	Beta ( 292, 1000)	[8]
Severe events (grade 3or 4)	Infusion-related reactions	Allergy or anaphylaxis	1.83%	First month on cetuximab	0% – 6%	Beta ( 183, 10000)	[8]
		Dyspnea	0.46%	First month on cetuximab	0%–4.65%	Beta ( 46, 10000)	[8]
		Hypotension	0.46%	First month on cetuximab	0%–4.65%	Beta ( 46, 10000)	[8]
	Skin reactions		8.67%	First month on cetuximab	4.70%–12.7%	Beta ( 867, 10000)	[8]
	Anorexia		0.61%	Time on cetuximab therapy	0%–1.34%	Beta ( 61, 10000)	[8]
	Hypomagnesemia		0.61%	Time on cetuximab therapy	0%–1.34%	Beta ( 61, 10000)	[8]
	Sepsis		0.61%	Time on cetuximab therapy	0%–1.34%	Beta ( 61, 10000)	[8]

± Beta(n, N). Beta distribution was used for other probability parameter estimates not shown in this table.